MARKET

ALEC

ALEC

Alector
NASDAQ
5.41
-0.03
-0.55%
Closed 16:05 05/20 EDT
OPEN
5.48
PREV CLOSE
5.44
HIGH
5.60
LOW
5.31
VOLUME
614.29K
TURNOVER
0
52 WEEK HIGH
9.07
52 WEEK LOW
3.660
MARKET CAP
521.44M
P/E (TTM)
-3.8949
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALEC last week (0513-0517)?
Weekly Report · 1d ago
The Limitations Of Anti-Inflammatory Drugs For The Treatment Of Alzheimer's Disease
Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's Disease is primarily caused by oxidative and nitrosative stress. Inhibiting the formation of peroxynitrite may stabilize early Alzheimer's and slow down the progression of moderate Alzheimer's.
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Alector (ALEC)
TipRanks · 5d ago
Weekly Report: what happened at ALEC last week (0506-0510)?
Weekly Report · 05/13 09:17
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Alector, Inc. (NASDAQ:ALEC) filed its first-quarter result last week. Revenues of US$16m arrived in line with expectations, but statutory losses per share were US$. The company is expected to report a 34% decline in revenue in the year to 2024. The consensus price target for Alector remains at US$ but is not expected to rise much.
Simply Wall St · 05/11 13:23
Barclays Sticks to Their Buy Rating for Alector (ALEC)
TipRanks · 05/10 10:05
Alector Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/09 18:09
Alector Price Target Cut to $35.00/Share From $41.00 by HC Wainwright & Co.
Dow Jones · 05/09 18:09
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.